Posted by Michael Wonder on 27 Jun 2018
ICER to evaluate whether price increases on prescription drugs are unsupported by new clinical evidence
27 June 2018 - Initial annual report to be issued in first quarter of 2019.
The ICER today announced the formation of an advisory group to guide the development of a report on US drug price increases that are unsupported by clinical evidence. ICER plans to issue its initial annual report on unsupported price increases during the first quarter of 2019.
"The federal government has expressed concern about drug price increases, and several states have already passed laws that will generate lists of drugs with substantial price increases so that policy makers and the public can seek greater transparency," said Steven D. Pearson, MD, MSc, President of ICER. "What isn't available to federal or state policymakers, to patients, or to other stakeholders is an explicit and independent approach to determining whether price increases are supported by new clinical evidence or other factors. That's the goal for this new initiative.
